{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:18:52Z","timestamp":1793848732586,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004919","name":"King Abdulaziz City for Science and Technology","doi-asserted-by":"publisher","award":["13-MED1765-20"],"award-info":[{"award-number":["13-MED1765-20"]}],"id":[{"id":"10.13039\/501100004919","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hereditary Multiple Exostoses (HME), also known as Multiple Osteochondromas (MO) is a rare genetic disorder characterized by multiple benign cartilaginous bone tumors, which are caused by mutations in the genes for exostosin glycosyltransferase 1 (<jats:italic>EXT1<\/jats:italic>) and exostosin glycosyltransferase 2 (<jats:italic>EXT2<\/jats:italic>). The genetic defects have not been studied in the Saudi patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim of study<\/jats:title>\n                <jats:p>We investigated mutation spectrum of <jats:italic>EXT1<\/jats:italic> and <jats:italic>EXT2<\/jats:italic> in 22 patients from 17 unrelated families.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Genomic DNA was extracted from peripheral leucocytes. The coding regions and intron\u2013exon boundaries of both <jats:italic>EXT1<\/jats:italic> and <jats:italic>EXT2<\/jats:italic> genes were screened for mutations by PCR-sequencing analysis. Gross deletions were analyzed by MLPA analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:italic>EXT1<\/jats:italic> mutations were detected in 6 families (35%) and 3 were novel mutations: c.739G\u2009&gt;\u2009T (p. E247*), c.1319delG (p.R440Lfs*4), and c.1786delA (p.S596Afs*25). <jats:italic>EXT2<\/jats:italic> mutations were detected in 7 families (41%) and 3 were novel mutations: c.541delG (p.D181Ifs*89), c.583delG (p.G195Vfs*75), and a gross deletion of approximately 10\u00a0kb including promoter and exon 1. Five patients from different families had no family history and carried de novo mutations (29%, 5\/17). No <jats:italic>EXT1<\/jats:italic> and <jats:italic>EXT2<\/jats:italic> mutations were found in the remaining four families. In total, <jats:italic>EXT1<\/jats:italic> and <jats:italic>EXT2<\/jats:italic> mutations were found in 77% (13\/17) of\u00a0Saudi HME patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:italic>EXT1<\/jats:italic> and <jats:italic>EXT2<\/jats:italic> mutations contribute significantly to the pathogenesis of HME in the Saudi population. In contrast to high mutation rate in <jats:italic>EXT 1<\/jats:italic> (65%) and low mutation rate in <jats:italic>EXT2<\/jats:italic> (25%) in other populations, the frequency of <jats:italic>EXT2<\/jats:italic> mutations are much higher (41%) and comparable to that of <jats:italic>EXT1<\/jats:italic> among Saudi patients. De novo mutations are also common and the six novel <jats:italic>EXT1<\/jats:italic>\/<jats:italic>EXT2<\/jats:italic> mutations further expands the mutation spectrum of HME.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01738-z","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T12:03:31Z","timestamp":1614254611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mutation spectrum of EXT1 and EXT2 in the Saudi patients with hereditary multiple exostoses"],"prefix":"10.1186","volume":"16","author":[{"given":"Zayed","family":"Al-Zayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roua A.","family":"Al-Rijjal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamya","family":"Al-Ghofaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda A.","family":"BinEssa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Alrabiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer","family":"Al-Hussainan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6999-0191","authenticated-orcid":false,"given":"Yufei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"issue":"7","key":"1738_CR1","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2106\/00004623-199407000-00005","volume":"76","author":"GA Schmale","year":"1994","unstructured":"Schmale GA, Conrad EU 3rd, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am. 1994;76(7):986\u201392.","journal-title":"J Bone Joint Surg Am"},{"issue":"3","key":"1738_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s11914-017-0355-2","volume":"15","author":"M Pacifici","year":"2017","unstructured":"Pacifici M. Hereditary multiple exostoses: new insights into pathogenesis, clinical complications, and potential treatments. Curr Osteoporos Rep. 2017;15(3):142\u201352.","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"1738_CR3","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s11999-015-4134-z","volume":"473","author":"CM Czajka","year":"2015","unstructured":"Czajka CM, DiCaprio MR. What is the proportion of patients with multiple hereditary exostoses who undergo malignant degeneration? Clin Orthop Relat Res. 2015;473(7):2355\u201361.","journal-title":"Clin Orthop Relat Res"},{"key":"1738_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1750-1172-3-3","volume":"3","author":"JV Bov\u00e9e","year":"2008","unstructured":"Bov\u00e9e JV. Multiple osteochondromas. Orphanet J Rare Dis. 2008;3:3.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"1738_CR5","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/humu.21123","volume":"30","author":"I Jennes","year":"2009","unstructured":"Jennes I, Pedrini E, Zuntini M, Mordenti M, Balkassmi S, Asteggiano CG, Casey B, Bakker B, Sangiorgi L, Wuyts W. Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat. 2009;30(12):1620\u20137.","journal-title":"Hum Mutat"},{"issue":"3","key":"1738_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<220::AID-HUMU2>3.0.CO;2-K","volume":"15","author":"W Wuyts","year":"2000","unstructured":"Wuyts W, Van Hul W. Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes. Hum Mutat. 2000;15(3):220\u20137.","journal-title":"Hum Mutat"},{"issue":"2","key":"1738_CR7","doi-asserted-by":"publisher","first-page":"E2036","DOI":"10.1002\/humu.21423","volume":"32","author":"K Szuhai","year":"2011","unstructured":"Szuhai K, Jennes I, de Jong D, Bov\u00e9e JV, Wiweger M, Wuyts W, Hogendoorn PC. Tiling resolution array-CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients. Hum Mutat. 2011;32(2):E2036-2049.","journal-title":"Hum Mutat"},{"issue":"4","key":"1738_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/gcc.22041","volume":"52","author":"CJ Waaijer","year":"2013","unstructured":"Waaijer CJ, Winter MG, Reijnders CM, de Jong D, John Ham S, Bov\u00e9e JV, Szuhai K. Intronic deletion and duplication proximal of the EXT1 gene: a novel causative mechanism for multiple osteochondromas. Genes Chromosomes Cancer. 2013;52(4):431\u20136.","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"1738_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/ajmg.a.35819","volume":"161A","author":"M Mordenti","year":"2013","unstructured":"Mordenti M, Ferrari E, Pedrini E, Fabbri N, Campanacci L, Muselli M, Sangiorgi L. Validation of a new multiple osteochondromas classification through Switching Neural Networks. Am J Med Genet A. 2013;161A(3):556\u201360.","journal-title":"Am J Med Genet A"},{"key":"1738_CR10","doi-asserted-by":"crossref","unstructured":"Cebeci AN, Zou M, BinEssa HA, Alzahrani AS, Al-Rijjal RA, Al-Enezi AF, Al-Mohanna FA, Cavalier E, Meyer BF, Shi Y: Mutation of SGK3, a novel regulator of renal phosphate transport, causes autosomal dominant hypophosphatemic rickets. J Clin Endocrinol Metab 2020, 105(6).","DOI":"10.1210\/clinem\/dgz260"},{"key":"1738_CR11","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/srep01346","volume":"3","author":"P Sarri\u00f3n","year":"2013","unstructured":"Sarri\u00f3n P, Sangorrin A, Urreizti R, Delgado A, Artuch R, Martorell L, Armstrong J, Anton J, Torner F, Vilaseca MA, et al. Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas. Sci Rep. 2013;3:1346.","journal-title":"Sci Rep"},{"issue":"6","key":"1738_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1365-2265.2011.04134.x","volume":"75","author":"H Raef","year":"2011","unstructured":"Raef H, Zou M, Baitei EY, Al-Rijjal RA, Kaya N, Al-Hamed M, Monies D, Abu-Dheim NN, Al-Hindi H, Al-Ghamdi MH, et al. A novel deletion of the MEN1 gene in a large family of multiple endocrine neoplasia type 1 (MEN1) with aggressive phenotype. Clin Endocrinol (Oxf). 2011;75(6):791\u2013800. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04134.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1738_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/jb\/mvn040","volume":"144","author":"S Nadanaka","year":"2008","unstructured":"Nadanaka S, Kitagawa H. Heparan sulphate biosynthesis and disease. J Biochem. 2008;144(1):7\u201314.","journal-title":"J Biochem"},{"key":"1738_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.matbio.2017.12.011","volume":"71\u201372","author":"M Pacifici","year":"2018","unstructured":"Pacifici M. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses. Matrix Biol. 2018;71\u201372:28\u201339.","journal-title":"Matrix Biol"},{"issue":"41","key":"1738_CR15","doi-asserted-by":"publisher","first-page":"26265","DOI":"10.1074\/jbc.273.41.26265","volume":"273","author":"T Lind","year":"1998","unstructured":"Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 1998;273(41):26265\u20138.","journal-title":"J Biol Chem"},{"key":"1738_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fendo.2018.00483","volume":"9","author":"A Nagarajan","year":"2018","unstructured":"Nagarajan A, Malvi P, Wajapeyee N. Heparan sulfate and heparan sulfate proteoglycans in cancer initiation and progression. Front Endocrinol (Lausanne). 2018;9:483.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1738_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/dvdy.24010","volume":"242","author":"J Huegel","year":"2013","unstructured":"Huegel J, Sgariglia F, Enomoto-Iwamoto M, Koyama E, Dormans JP, Pacifici M. Heparan sulfate in skeletal development, growth, and pathology: the case of hereditary multiple exostoses. Dev Dyn. 2013;242(9):1021\u201332.","journal-title":"Dev Dyn"},{"issue":"1","key":"1738_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1615\/CritRevEukaryotGeneExpr.v15.i1.30","volume":"15","author":"MC Farach-Carson","year":"2005","unstructured":"Farach-Carson MC, Hecht JT, Carson DD. Heparan sulfate proteoglycans: key players in cartilage biology. Crit Rev Eukaryot Gene Expr. 2005;15(1):29\u201348.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"45","key":"1738_CR19","doi-asserted-by":"publisher","first-page":"32802","DOI":"10.1074\/jbc.M703560200","volume":"282","author":"M Busse","year":"2007","unstructured":"Busse M, Feta A, Presto J, Wil\u00e9n M, Gr\u00f8nning M, Kjell\u00e9n L, Kusche-Gullberg M. Contribution of EXT1, EXT2, and EXTL3 to heparan sulfate chain elongation. J Biol Chem. 2007;282(45):32802\u201310.","journal-title":"J Biol Chem"},{"issue":"2","key":"1738_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1073\/pnas.97.2.668","volume":"97","author":"C McCormick","year":"2000","unstructured":"McCormick C, Duncan G, Goutsos KT, Tufaro F. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci USA. 2000;97(2):668\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1738_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/embo-reports\/kvd045","volume":"1","author":"C Senay","year":"2000","unstructured":"Senay C, Lind T, Muguruma K, Tone Y, Kitagawa H, Sugahara K, Lidholt K, Lindahl U, Kusche-Gullberg M. The EXT1\/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis. EMBO Rep. 2000;1(3):282\u20136.","journal-title":"EMBO Rep"},{"issue":"7","key":"1738_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/glycob\/cwt1024","volume":"23","author":"EKMF Anower","year":"2013","unstructured":"Anower EKMF, Matsumoto K, Habuchi H, Morita H, Yokochi T, Shimizu K, Kimata K. Glycosaminoglycans in the blood of hereditary multiple exostoses patients: half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application. Glycobiology. 2013;23(7):865\u201376. https:\/\/doi.org\/10.1093\/glycob\/cwt1024 (Epub 2013 Mar 1020).","journal-title":"Glycobiology"},{"issue":"4","key":"1738_CR23","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.2353\/ajpath.2010.100296","volume":"177","author":"CM Reijnders","year":"2010","unstructured":"Reijnders CM, Waaijer CJ, Hamilton A, Buddingh EP, Dijkstra SP, Ham J, Bakker E, Szuhai K, Karperien M, Hogendoorn PC, et al. No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas. Am J Pathol. 2010;177(4):1946\u201357.","journal-title":"Am J Pathol"},{"issue":"5","key":"1738_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/jnci\/djk067","volume":"99","author":"L Hameetman","year":"2007","unstructured":"Hameetman L, Szuhai K, Yavas A, Knijnenburg J, van Duin M, van Dekken H, Taminiau AH, Cleton-Jansen AM, Bovee JV, Hogendoorn PC. The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst. 2007;99(5):396\u2013406.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1738_CR25","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1073\/pnas.0910875107","volume":"107","author":"KB Jones","year":"2010","unstructured":"Jones KB, Piombo V, Searby C, Kurriger G, Yang B, Grabellus F, Roughley PJ, Morcuende JA, Buckwalter JA, Capecchi MR, et al. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci USA. 2010;107(5):2054\u20139. https:\/\/doi.org\/10.1073\/pnas.0910875107 (Epub 0910872009 Dec 0910875122).","journal-title":"Proc Natl Acad Sci USA"},{"issue":"25","key":"1738_CR26","doi-asserted-by":"publisher","first-page":"19227","DOI":"10.11074\/jbc.M19110.105338","volume":"285","author":"Y Matsumoto","year":"2010","unstructured":"Matsumoto Y, Matsumoto K, Irie F, Fukushi J, Stallcup WB, Yamaguchi Y. Conditional ablation of the heparan sulfate-synthesizing enzyme Ext1 leads to dysregulation of bone morphogenic protein signaling and severe skeletal defects. J Biol Chem. 2010;285(25):19227\u201334. https:\/\/doi.org\/10.11074\/jbc.M19110.105338 (Epub 102010 Apr 105319).","journal-title":"J Biol Chem"},{"issue":"1","key":"1738_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bone.2013.1008.1012","volume":"57","author":"F Sgariglia","year":"2013","unstructured":"Sgariglia F, Candela ME, Huegel J, Jacenko O, Koyama E, Yamaguchi Y, Pacifici M, Enomoto-Iwamoto M. Epiphyseal abnormalities, trabecular bone loss and articular chondrocyte hypertrophy develop in the long bones of postnatal Ext1-deficient mice. Bone. 2013;57(1):220\u201331. https:\/\/doi.org\/10.1016\/j.bone.2013.1008.1012 (Epub 2013 Aug 1017).","journal-title":"Bone"},{"issue":"26","key":"1738_CR28","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1038\/onc.2010.135","volume":"29","author":"M Zuntini","year":"2010","unstructured":"Zuntini M, Pedrini E, Parra A, Sgariglia F, Gentile FV, Pandolfi M, Alberghini M, Sangiorgi L. Genetic models of osteochondroma onset and neoplastic progression: evidence for mechanisms alternative to EXT genes inactivation. Oncogene. 2010;29(26):3827\u201334.","journal-title":"Oncogene"},{"issue":"9","key":"1738_CR29","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/onc.2011.311","volume":"31","author":"CE de Andrea","year":"2012","unstructured":"de Andrea CE, Reijnders CM, Kroon HM, de Jong D, Hogendoorn PC, Szuhai K, Bov\u00e9e JV. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene. 2012;31(9):1095\u2013104.","journal-title":"Oncogene"},{"key":"1738_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bone.2016.09.005","volume":"92","author":"DL Cousminer","year":"2016","unstructured":"Cousminer DL, Arkader A, Voight BF, Pacifici M, Grant SFA. Assessing the general population frequency of rare coding variants in the EXT1 and EXT2 genes previously implicated in hereditary multiple exostoses. Bone. 2016;92:196\u2013200.","journal-title":"Bone"},{"key":"1738_CR31","doi-asserted-by":"publisher","unstructured":"Ishimaru D, Gotoh M, Takayama S, Kosaki R, Matsumoto Y, Narimatsu H, Sato T, Kimata K, Akiyama H, Shimizu K et al: Large-scale mutational analysis in the EXT1 and EXT2 genes for Japanese patients with multiple osteochondromas. BMC Genet 2016, 17:52. doi:https:\/\/doi.org\/10.1186\/s12863-12016-10359-12864.","DOI":"10.1186\/s12863-12016-10359-12864"},{"key":"1738_CR32","doi-asserted-by":"publisher","unstructured":"Sarrion P, Sangorrin A, Urreizti R, Delgado A, Artuch R, Martorell L, Armstrong J, Anton J, Torner F, Vilaseca MA et al. Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas. Sci Rep 2013, 3:1346. doi:https:\/\/doi.org\/10.1038\/srep01346.","DOI":"10.1038\/srep01346"},{"issue":"2","key":"1738_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.gene.2012.11.055","volume":"515","author":"M Ciavarella","year":"2013","unstructured":"Ciavarella M, Coco M, Baorda F, Stanziale P, Chetta M, Bisceglia L, Palumbo P, Bengala M, Raiteri P, Silengo M, et al. 20 novel point mutations and one large deletion in EXT1 and EXT2 genes: report of diagnostic screening in a large Italian cohort of patients affected by hereditary multiple exostosis. Gene. 2013;515(2):339\u201348.","journal-title":"Gene"},{"issue":"2","key":"1738_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s13353-014-0195-z","volume":"55","author":"A Jamsheer","year":"2014","unstructured":"Jamsheer A, Socha M, Sowi\u0144ska-Seidler A, Telega K, Trzeciak T, Latos-Biele\u0144ska A. Mutational screening of EXT1 and EXT2 genes in Polish patients with hereditary multiple exostoses. J Appl Genet. 2014;55(2):183\u20138.","journal-title":"J Appl Genet"},{"issue":"3","key":"1738_CR35","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1086\/515505","volume":"61","author":"C Philippe","year":"1997","unstructured":"Philippe C, Porter DE, Emerton ME, Wells DE, Simpson AH, Monaco AP. Mutation screening of the EXT1 and EXT2 genes in patients with hereditary multiple exostoses. Am J Hum Genet. 1997;61(3):520\u20138.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"1738_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.arcmed.2013.09.008","volume":"44","author":"QL Kang","year":"2013","unstructured":"Kang QL, Xu J, Zhang Z, He JW, Fu WZ, Zhang ZL. Mutation screening for the EXT1 and EXT2 genes in Chinese patients with multiple osteochondromas. Arch Med Res. 2013;44(7):542\u20138.","journal-title":"Arch Med Res"},{"issue":"2","key":"1738_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/ng1095-137","volume":"11","author":"J Ahn","year":"1995","unstructured":"Ahn J, Ludecke HJ, Lindow S, Horton WA, Lee B, Wagner MJ, Horsthemke B, Wells DE. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet. 1995;11(2):137\u201343.","journal-title":"Nat Genet"},{"issue":"1","key":"1738_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12881-017-0488-2","volume":"18","author":"Y Li","year":"2017","unstructured":"Li Y, Wang J, Wang Z, Tang J, Yu T. A genotype-phenotype study of hereditary multiple exostoses in forty-six Chinese patients. BMC Med Genet. 2017;18(1):126.","journal-title":"BMC Med Genet"},{"issue":"1","key":"1738_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/sj.ejhg.5200409","volume":"8","author":"C Dobson-Stone","year":"2000","unstructured":"Dobson-Stone C, Cox RD, Lonie L, Southam L, Fraser M, Wise C, Bernier F, Hodgson S, Porter DE, Simpson AH, et al. Comparison of fluorescent single-strand conformation polymorphism analysis and denaturing high-performance liquid chromatography for detection of EXT1 and EXT2 mutations in hereditary multiple exostoses. Eur J Hum Genet. 2000;8(1):24\u201332.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"1738_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2353\/jmoldx.2008.070086","volume":"10","author":"I Jennes","year":"2008","unstructured":"Jennes I, Entius MM, Van Hul E, Parra A, Sangiorgi L, Wuyts W. Mutation screening of EXT1 and EXT2 by denaturing high-performance liquid chromatography, direct sequencing analysis, fluorescence in situ hybridization, and a new multiplex ligation-dependent probe amplification probe set in patients with multiple osteochondromas. J Mol Diagn. 2008;10(1):85\u201392.","journal-title":"J Mol Diagn"},{"key":"1738_CR41","doi-asserted-by":"publisher","unstructured":"Jennes I, de Jong D, Mees K, Hogendoorn PC, Szuhai K, Wuyts W: Breakpoint characterization of large deletions in EXT1 or EXT2 in 10 multiple osteochondromas families. BMC Med Genet 2011, 12:85 doi:https:\/\/doi.org\/10.1186\/1471-2350-1112-1185.","DOI":"10.1186\/1471-2350-1112-1185"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01738-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T12:11:12Z","timestamp":1614255072000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01738-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01738-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of King Faisal Specialist Hospital and Research Centre (RAC #2170 027). Written consent was obtained from the patients or guardian of the patients before enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}